CertaPeptides MOTS-c and NAD+ Promo-Code/Product FAQ: LOOT30 for Up to 30% Off

MOTS-c and NAD+ are often grouped together in discussions of mitochondrial function, cellular-energy metabolism, metabolic signaling, and aging biology, but they are not interchangeable research materials. MOTS-c is a mitochondrially encoded 16-amino-acid peptide with published work examining metabolic signaling and mitochondrial-to-nuclear communication. NAD+, by contrast, is nicotinamide adenine dinucleotide, a central metabolic coenzyme involved in redox reactions and multiple signaling systems. SS-31, glutathione, AICAR, Epitalon, FOXO4-related compounds, and other research materials sometimes appear in the same broader research conversation, yet each belongs to a distinct molecular and experimental category.

Qualified laboratory researchers reviewing the CertaPeptides catalog can access the CertaPeptides LOOT30 research catalog and use promo code LOOT30 for up to 30% off. The commercial offer should come after—not before—evaluation of molecular identity, study relevance, lot documentation, analytical records, handling requirements, and institutional research rules.

Affiliate disclosure: This post contains an affiliate link; the publisher may earn a commission from qualifying purchases.

Research-use notice: CertaPeptides products discussed here are intended for controlled in-vitro and laboratory research by qualified researchers. They are not for human or veterinary use, consumption, administration, diagnosis, treatment, cure, prevention, clinical application, food, supplements, cosmetics, or personal experimentation.

What is MOTS-c?

MOTS-c is short for mitochondrial open reading frame of the 12S rRNA-c. The original 2015 Cell Metabolism paper described it as a 16-amino-acid peptide encoded within mitochondrial DNA and examined its role in metabolic homeostasis. In cell and animal experiments, the investigators connected MOTS-c signaling with pathways involving folate metabolism, de novo purine synthesis, skeletal-muscle metabolism, and AMPK activity. Those findings established an important research direction, but they should not be converted into claims that a commercial MOTS-c research vial has demonstrated human therapeutic effects.

MOTS-c is especially interesting because it expands the conventional view of mitochondria. Mitochondria are widely known for their role in cellular energy production, but mitochondrial-derived peptides support a broader model in which mitochondria also participate in inter-organelle and organelle-to-nucleus signaling. A later Cell Metabolism study reported that MOTS-c could translocate to the nucleus under metabolic stress and influence nuclear gene expression. That work helps explain why mitochondrial peptides are studied not simply as static metabolic molecules but as components of stress-response signaling networks.

This distinction matters for research design. A study involving MOTS-c may focus on mitochondrial signaling, AMPK-related pathways, metabolic stress, transcriptional responses, skeletal-muscle biology, or communication between mitochondrial and nuclear systems. Those questions are different from merely asking whether a compound increases or decreases a single biomarker.

CertaPeptides currently lists MOTS-c within its copper and mitochondrial research category. Its public product page describes research-grade lyophilized MOTS-c, a supplier batch specification of at least 98% purity, and selected-lot third-party testing. The live COA system also currently displays an independently tested MOTS-c lot with a reported chromatographic purity of 99.266% and measured content of 40.37 mg for a 40 mg-labelled lot. Those numbers describe that specific tested lot; they should not be generalized automatically to every past or future MOTS-c vial.

Why lot-specific documentation matters for MOTS-c

Research procurement should distinguish between the name of the molecule, the supplier's product specification, and the analytical information associated with an individual batch.

A product name tells a researcher what the material is supposed to be. A specification tells the researcher what standard the supplier says the material should meet. A lot-specific analytical report provides evidence about the sample that was actually tested. These layers are related, but they are not identical.

CertaPeptides states that its products ship according to published supplier batch specifications while selected lots receive independent analytical testing. The current public verification area includes MOTS-c among the independently tested materials. This is useful because a researcher can compare the vial or batch information against the associated record rather than relying only on general marketing language.

For analytical interpretation, purity and measured content should also remain separate concepts. An HPLC purity result describes the relative chromatographic composition under the conditions of the assay. Measured content addresses how much target material was quantified in the tested sample. A very high chromatographic purity percentage does not, by itself, establish that the vial contains exactly the nominal mass printed on the label.

The CertaPeptides MOTS-c record illustrates why both fields can be useful: the public record reports a purity percentage and a measured mass. A documentation-focused laboratory should therefore match the lot code, confirm what analytical method was used, distinguish relative purity from quantity, and retain the relevant record with procurement documentation.

Researchers who want a more narrowly focused comparison can also review the previously published CertaPeptides MOTS-c versus SS-31 research comparison. The useful point is not that one molecule is universally “better,” but that the two belong to different mitochondrial research frameworks.

What is NAD+?

NAD+—nicotinamide adenine dinucleotide—is fundamentally different from MOTS-c. It is not a conventional peptide. NAD+ is a coenzyme used in redox chemistry and is also consumed by several classes of signaling enzymes.

That means NAD+ participates in multiple layers of cellular biology. It is involved in metabolic oxidation-reduction reactions that support energy metabolism, while NAD+-dependent enzymes connect it with processes such as DNA repair, chromatin regulation, cellular stress responses, and signaling.

A major review of NAD+ biology describes it as a central coenzyme for redox reactions and a substrate or cofactor for systems including sirtuins, CD38, and poly(ADP-ribose) polymerases. That review also discusses associations among NAD+ metabolism, tissue homeostasis, cellular senescence, immune function, and aging biology.

This broad biological relevance is one reason NAD+ appears frequently in aging and metabolic research. It is also why simplistic statements such as “NAD+ is an anti-aging molecule” are scientifically inadequate. A biochemical pathway can be associated with aging biology without establishing that increasing one molecule produces a predictable human anti-aging outcome.

Recent reviews reinforce that distinction. A 2025 Nature Metabolism review noted that although NAD+ decline has been implicated in aging and age-related disorders, consistent evidence for age-related NAD+ decline in humans is available from only a limited number of studies, and clinical trials of NAD+ precursor supplementation have generally shown more limited efficacy than the preclinical literature might suggest.

That evidence gap is particularly important for research-only product content. Results involving nicotinamide riboside, nicotinamide mononucleotide, direct NAD+ exposure, genetic manipulation of NAD+ metabolism, or rodent aging models should not be treated as if they are interchangeable experimental interventions.

MOTS-c versus NAD+: the essential distinction

The simplest comparison is that MOTS-c is a signaling peptide, while NAD+ is a metabolic coenzyme.

MOTS-c research asks questions about a mitochondrially encoded peptide and its signaling behavior. NAD+ research asks questions about redox metabolism, NAD+-dependent enzymes, biosynthesis, consumption, compartmentalization, and the consequences of changing NAD+ availability.

Because both intersect with cellular-energy biology, it is easy to compress them into one vague “mitochondrial” category. That would obscure the scientific question.

A useful conceptual comparison is:

Research feature	MOTS-c	NAD+
Molecular category	Mitochondrial-derived peptide	Metabolic coenzyme
Core research context	Mitochondrial signaling and metabolic stress	Redox metabolism and NAD+-dependent signaling
Important associated pathways	AMPK-related signaling, purine metabolism, mitochondrial-to-nuclear communication	Sirtuins, PARPs, CD38, redox reactions, energy metabolism
Evidence interpretation	Separate cell, animal and human observations	Separate biochemical, animal, precursor-supplementation and human evidence
Key experimental risk	Treating preclinical signaling findings as human outcomes	Treating NAD+ biology or precursor studies as proof of broad anti-aging effects
Procurement emphasis	Identity, lot, purity, measured content, experimental suitability	Exact material identity, format, analytical documentation and study-specific suitability

This is why an experiment designed around mitochondrial signaling cannot simply substitute NAD+ for MOTS-c, or vice versa, without changing the scientific question.

How SS-31 differs from MOTS-c

SS-31 is another molecule frequently placed beside MOTS-c in mitochondrial-research discussions, but its mechanism and experimental rationale are different.

SS-31 is also known in the scientific literature as elamipretide. It is a synthetic mitochondria-targeting tetrapeptide rather than a peptide encoded by mitochondrial DNA. Published work and reviews describe its interaction with cardiolipin, an inner-mitochondrial-membrane phospholipid, and research concerning mitochondrial membrane architecture, oxidative stress, bioenergetics, and related disease models.

CertaPeptides currently lists SS-31 as a research product and its public COA system displays a tested SS-31 lot reporting 99.841% purity and 11.17 mg measured content for a nominal 10 mg lot. Again, that analytical result belongs to the listed tested lot and should not be generalized across unrelated batches.

The distinction can therefore be stated cleanly: MOTS-c is a mitochondrially encoded signaling peptide; SS-31 is a synthetic mitochondria-targeting peptide studied particularly in relation to mitochondrial membranes and cardiolipin.

Researchers wanting a broader explanation of where these compounds sit beside NAD+ and glutathione can review the previously published MOTS-c, SS-31, NAD and glutathione research distinctions article.

Where glutathione fits

Glutathione belongs to yet another research category. It is a tripeptide composed of glutamate, cysteine, and glycine and is central to cellular redox chemistry. Researchers commonly examine glutathione in relation to antioxidant systems, thiol-redox balance, oxidative stress, detoxification reactions, and maintenance of cellular redox state.

That makes glutathione relevant to mitochondrial and cellular-stress research without making it mechanistically equivalent to either MOTS-c or SS-31.

The important research lesson is that “mitochondrial,” “metabolic,” “cellular-energy,” “redox,” and “aging” are overlapping themes rather than synonyms. Experimental materials should be categorized by molecular identity and mechanism, not merely by the broad topic under which they are marketed or discussed.

CertaPeptides currently lists Glutathione 1500 mg in its live catalog, and its independent-verification page includes a glutathione test result reporting 98.76% purity and measured content of 1527.43 mg for the listed tested lot.

What about AICAR?

AICAR is relevant to this discussion because AMPK is repeatedly encountered in metabolic research.

In the original MOTS-c research, inhibition of de novo purine biosynthesis was associated with accumulation of AICAR and activation of AMPK. That does not mean MOTS-c and AICAR are the same research material or that experiments involving one can automatically answer questions intended for the other.

AICAR is better understood as a metabolic research compound connected with cellular-energy sensing and AMPK-related experimental models. When researchers encounter MOTS-c and AICAR in the same literature, the useful question is how the study links mitochondrial signaling, nucleotide metabolism, cellular-energy status, and AMPK—not which name sounds more closely associated with metabolism.

What about 5-amino-1MQ?

5-amino-1MQ is typically discussed in relation to nicotinamide N-methyltransferase, or NNMT, research. It therefore belongs to a distinct metabolic-research framework.

It should not be described as a peptide simply because it may appear in a research-supplier catalog containing many peptides. The chemistry of a research compound matters. Correct classification prevents a catalog category from replacing actual molecular identity.

This is especially important when comparing materials across pathways. A researcher interested in NAD metabolism, mitochondrial-derived peptides, NNMT biology, or AMPK signaling is investigating connected but non-identical systems.

FOXO4 and cellular-senescence research

FOXO4 belongs to the forkhead box O family of transcription factors and appears in cellular-senescence research. FOXO4-related experimental compounds are sometimes promoted online with sweeping “longevity” or “anti-aging” labels. Those labels can obscure the narrower scientific question.

Cellular senescence is a specific biological phenomenon, and research into FOXO4-related interactions should be interpreted at the level of the study model, molecular target, cell type, and endpoint. It should not be converted automatically into claims about rejuvenation or lifespan extension in people.

The same evidence discipline applies to MOTS-c and NAD+. Aging biology includes mitochondrial function, redox balance, nutrient sensing, cellular senescence, DNA repair, proteostasis, epigenetic regulation, and many other systems. No single research compound represents the entire biology of aging.

Where Epitalon fits

Epitalon is a synthetic tetrapeptide frequently discussed in telomere and aging-biology research. It is chemically and mechanistically distinct from MOTS-c, NAD+, SS-31, and glutathione.

Its relevance here is therefore comparative. Researchers encountering several “cellular aging” products in the same catalog should not infer that they operate through the same pathway or answer the same experimental question.

CertaPeptides currently includes Epitalon in its live research catalog, while its public independent-testing area lists tested Epitalon lots among its available analytical records.

MOTS-c and the language of “metabolic aging”

The phrase “metabolic aging” can refer to age-associated changes in mitochondrial function, insulin signaling, substrate utilization, muscle metabolism, nutrient sensing, redox balance, cellular stress responses, and numerous related pathways.

MOTS-c has attracted interest partly because published studies connect a mitochondrial-derived peptide with several of these systems. But scientific writing should preserve the hierarchy of evidence.

The 2015 MOTS-c paper reported metabolic effects in experimental models, including mice. The 2018 nuclear-translocation paper investigated how MOTS-c participates in a cellular response to metabolic stress. Those are important mechanistic findings. They do not establish that a MOTS-c research product prevents metabolic aging in humans.

A responsible laboratory article therefore describes MOTS-c as a mitochondrial-derived peptide studied in metabolic, mitochondrial, stress-response, and aging-related experimental biology.

It does not describe MOTS-c as a proven anti-aging therapy.

NAD+ and the language of “cellular aging”

NAD+ requires similar care.

NAD+ metabolism intersects with sirtuins, PARPs, DNA-damage responses, CD38 activity, mitochondrial biology, energy metabolism, and other systems related to aging. Some preclinical studies have produced striking results when NAD+ metabolism is altered.

Human evidence is more complicated.

A 2021 review of NAD+ precursors emphasized strong preclinical interest while also distinguishing those results from the developing clinical evidence. More recent clinical reviews continue to note limitations in the human evidence base and the need for tissue-specific, intervention-specific research.

A laboratory researcher should therefore specify exactly what is being studied. Direct NAD+ exposure is not the same intervention as nicotinamide riboside. Nicotinamide mononucleotide is not identical to NAD+. A change in circulating metabolite concentration is not automatically evidence of altered NAD+ biology in every tissue.

Good research language is precise enough to preserve those distinctions.

Understanding CertaPeptides product documentation

For a research buyer, a product page is only one part of procurement.

The more useful documentation chain is:

product identity → batch identity → specification → analytical result → experimental suitability.

CertaPeptides currently describes a system in which every product line ships according to a supplier batch specification and selected lots receive independent analytical verification. Its public verification page links independent reports for numerous compounds, including MOTS-c and SS-31.

Researchers should pay attention to exactly what a document demonstrates.

An HPLC chromatogram can provide information about chromatographic purity under specified conditions. Mass-spectrometric analysis can support molecular-identity assessment. Quantitative content analysis can address how much target material is present. None of these measurements automatically establishes sterility, biological activity in a particular assay, suitability for a specific experimental system, or every other quality characteristic a laboratory might require.

Documentation should therefore be matched to the actual research risk.

A laboratory measuring pathway activation in cultured cells may have different documentation priorities from a laboratory conducting analytical-method development, stability testing, receptor-binding work, or comparative biochemical studies.

This is also why researchers should retain batch records instead of relying on screenshots or generic product descriptions.

For additional background on the general research context, the earlier MOTS-c mitochondrial signaling and metabolism overview provides a useful supporting reference, while the more recent cellular, mitochondrial and metabolic signaling explainer gives broader non-specialist context.

How should a researcher compare MOTS-c and SS-31?

The comparison should start with the study hypothesis.

If the hypothesis concerns a mitochondrially encoded peptide acting as a signaling molecule and participating in metabolic-stress responses, MOTS-c is the more direct conceptual subject.

If the hypothesis concerns a mitochondria-targeted tetrapeptide, cardiolipin interactions, inner-membrane integrity, mitochondrial bioenergetics, or related oxidative-stress models, SS-31 belongs to the more relevant literature framework.

That does not make either compound universally preferable. It means they answer different experimental questions.

This distinction is more informative than a generalized “MOTS-c vs SS-31” ranking.

How should a researcher compare MOTS-c and NAD+?

Again, start with the biological question.

MOTS-c is useful when the subject is mitochondrial-derived peptide signaling.

NAD+ is useful when the subject is redox chemistry, cellular-energy metabolism, NAD+-dependent enzymatic systems, biosynthesis or degradation of NAD+, or how changing NAD+ availability affects an experimental model.

There can be conceptual overlap because mitochondrial signaling, AMPK, redox balance, nutrient sensing, and NAD+-dependent pathways influence one another. But overlap is not equivalence.

A good experimental design defines the independent variable first and chooses the material afterward.

LOOT30 and the research-procurement sequence

Promo code LOOT30 provides up to 30% off under the campaign terms, but price is only one layer of research procurement.

A laboratory should first identify the required material and experimental question. The next step is to inspect the current product page and associated documentation. Researchers should then match the lot or batch, review the relevant analytical records, check whether the material format fits the protocol, verify institutional procurement rules, and confirm current shipping coverage.

Only after those scientific and logistical questions are resolved should the discount influence the commercial decision.

This order matters because a lower acquisition price cannot rescue a mismatched molecule, an unsupported experimental assumption, or inadequate documentation.

For qualified researchers who have already completed that assessment, LOOT30 can reduce eligible CertaPeptides purchasing costs by up to 30% without changing the scientific decision process.

Current CertaPeptides shipping coverage

CertaPeptides' live shipping page currently states that it serves all 27 European Union member states plus Switzerland, the United Kingdom, Iceland, and Serbia. The same page describes different carrier arrangements by destination and states that shipments include tracking.

Because shipping policies can change, laboratories should use the current shipping page rather than relying on an older article, archived screenshot, or prior order.

Shipping availability also does not establish that a research material may lawfully be imported, possessed, or used for a particular purpose in every destination. Institutional procurement requirements, customs rules, national law, and research-governance requirements remain separate questions.

CertaPeptides' current returns information also describes a 14-day return framework for eligible unopened products, along with procedures for damaged shipments and return authorization. Laboratories should read the live policy before ordering because opening, storage, handling, and other conditions may affect return eligibility.

Does the CertaPeptides MOTS-c page show independent testing?

Yes. The current public CertaPeptides material includes independently tested MOTS-c records, and the COA area lists a tested MOTS-c lot with a reported 99.266% purity result and measured content of 40.37 mg for the listed 40 mg lot.

The correct interpretation is lot-specific: that report documents the tested sample identified by the associated record.

It should not be rewritten as “every MOTS-c vial is 99.266% pure.”

Does CertaPeptides have SS-31?

The live CertaPeptides shop currently lists SS-31 among its copper and mitochondrial research products. Its public verification system also displays independent SS-31 analytical records.

SS-31 should nevertheless be researched independently from MOTS-c because its chemistry, literature base, and proposed mitochondrial interactions differ.

Is NAD+ a peptide?

No.

NAD+ is nicotinamide adenine dinucleotide, a metabolic coenzyme.

Its appearance in peptide-adjacent research discussions or a research supplier's broader cellular-energy ecosystem does not change its chemical identity.

That distinction is important because calling every research product a “peptide” can introduce errors into literature searches, procurement records, experimental descriptions, and scientific communication.

Does NAD+ decline with age?

The answer requires qualification.

Age-associated changes in NAD+ have been reported in experimental organisms and some human tissues, and NAD+ metabolism is a major area of aging research. However, a recent Nature Metabolism review concluded that consistent evidence for age-related NAD+ decline in humans has been demonstrated in only a limited number of studies and that the human literature remains comparatively sparse and tissue-dependent.

Therefore, “NAD+ always falls with age in humans” is too broad.

A stronger scientific statement is that age-related NAD+ metabolism is actively studied and appears to vary by tissue, biological context, measurement method, and study population.

Do NAD+ precursors prove anti-aging effects in humans?

No such broad conclusion is supported.

Human studies have examined precursors such as nicotinamide riboside and nicotinamide mononucleotide, but increasing NAD+-related metabolites or demonstrating biochemical target engagement is not equivalent to demonstrating broad anti-aging efficacy.

Recent reviews note that human efficacy has generally been more limited and heterogeneous than the preclinical literature might suggest.

This distinction should remain explicit in research-focused content.

Is MOTS-c proven to extend human lifespan?

No.

MOTS-c is scientifically interesting because of its mitochondrial origin and published findings involving metabolic homeostasis, stress signaling, AMPK-related pathways, and mitochondrial-to-nuclear communication.

Those studies do not establish human lifespan extension.

Calling MOTS-c a “longevity peptide” without qualification can therefore overstate the evidence. “Mitochondrial-derived peptide studied in metabolic and aging-related biology” is more accurate.

Are MOTS-c and SS-31 interchangeable?

No.

MOTS-c is a mitochondrially encoded signaling peptide.

SS-31 is a synthetic mitochondria-targeting tetrapeptide associated particularly with cardiolipin and mitochondrial-membrane research.

Their overlap is mitochondrial biology, not molecular identity or experimental function.

Can one COA represent every batch?

No.

Analytical data should be tied to the specific sample or lot tested.

If a researcher orders a later batch, the correct practice is to match the received batch identifier with the corresponding documentation rather than assuming an older report automatically characterizes the new material.

This principle is particularly important when a supplier publishes multiple historical analytical records.

What does “research use only” mean here?

It means the materials discussed in this article are being addressed as laboratory research materials rather than consumer wellness products or medicines.

This article does not provide dosing, cycling, stacking, injection, administration, reconstitution, treatment, weight-loss, performance-enhancement, or self-experimentation instructions.

Scientific context about a molecule does not transform a research product into a clinically approved therapy.

Why the evidence hierarchy matters

MOTS-c and NAD+ illustrate why modern research-product content needs a visible evidence hierarchy.

In-vitro findings can reveal mechanisms.

Animal experiments can show effects in intact biological systems.

Observational human studies can identify associations.

Controlled human trials can evaluate defined interventions in defined populations.

These levels of evidence answer different questions.

The existence of an intriguing mouse result does not mean the same outcome occurs in humans. A biochemical association does not prove a clinical benefit. A pathway linked with aging does not automatically become an “anti-aging treatment.”

The strongest research communication keeps those boundaries intact.

The same principle applies when evaluating a supplier. A product description establishes what is being sold. A supplier specification defines a stated quality target. A third-party analytical report provides information about a tested sample. None of those documents, individually, proves that every experimental application is appropriate.

The laboratory remains responsible for defining the question, selecting the correct material, assessing documentation, and designing the experiment.

Final perspective

MOTS-c, NAD+, SS-31, glutathione, AICAR, 5-amino-1MQ, FOXO4-related compounds, and Epitalon can all appear in conversations about metabolic, mitochondrial, cellular-stress, or aging biology. Their shared research context should not erase their differences.

MOTS-c is a mitochondrially encoded peptide studied in signaling and metabolic-stress biology.

NAD+ is a central metabolic coenzyme involved in redox chemistry and NAD+-dependent signaling systems.

SS-31 is a synthetic mitochondria-targeting tetrapeptide associated with cardiolipin and mitochondrial-membrane research.

Glutathione is a tripeptide central to cellular redox systems.

AICAR belongs to cellular-energy and AMPK-related research.

5-amino-1MQ is associated with NNMT-centered metabolic research.

FOXO4-related compounds are discussed in cellular-senescence research.

Epitalon belongs to a different peptide and aging-biology literature.

The practical research question is therefore not “Which is the best anti-aging compound?” It is “Which molecular system does the experiment actually intend to investigate, and what evidence and documentation are needed to study it responsibly?”

For qualified laboratory researchers who have already answered those scientific and procurement questions, the CertaPeptides LOOT30 research catalog is available with promo code LOOT30 for up to 30% off.

All products discussed are strictly for controlled laboratory and in-vitro research. They are not for human or veterinary use, consumption, administration, diagnosis, treatment, cure, prevention, clinical application, supplements, cosmetics, or personal experimentation.